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Targeting chromatin regulators for the treatment of malignancies has shown great promise, but also revealed
significant challenges. By employing an elegant shRNA screen and a selective pharmacological inhibitor,
a recent study published in Nature establishes the bromodomain protein Brd4 as novel target in acute
myeloid leukemia (AML).Short hairpin RNA screens to identify crit-
ical regulators of cancer cell growth are
a promising methodology but have been
technically challenging. In particular,
such screens can be biased by selections
introduced when shRNAs are introduced
into cells. The recent paper by Zuber
and colleagues combines a series of crit-
ical variations on the approach to identify
the bromodomain protein Brd4 as a regu-
lator of c-Myc and a viable therapeutic
target for acute myeloid leukemia (AML)
(Zuber et al., 2011b). A critical element in
the screen is the use of vectors that place
shRNAs on a regulatable promoter to
avoid selection bias (Zuber et al., 2011a).
Other important features of the study are
the well-defined biologic system, in vivo
confirmation of selected targets, and the
serendipitous ability to confirm the results
with the recently described Brd4 inhibitor
JQ1 (Filippakopoulos et al., 2010). This
combination of elements should stimulate
a renewed and better-educated interest in
short hairpin screens for identifying
targets for cancer therapy.
Genomic alterations, along with the
subversion of epigenetic pathways, can
lead to AML, a particularly aggressive
form of leukemia with relatively few treat-
ment options. Zuber et al. developed a
strategy designed to specifically inhibit
the growth of leukemic cells by inhibiting
known regulators of chromatin function.
A circumscribed custom library of 1100
shRNAs against 243 known chromatin
regulators driven from an inducible vector
was introduced intomurine leukemic cells
coexpressing MLL-AF9 and an activatedform of Nras (G12D). Transduced cells
were cultured for two weeks under condi-
tions allowing the expression of shRNAs.
Subsequent profiling of shRNAs by deep
sequencing identified shRNAs that were
underrepresented and whose targets
thus deemed essential for leukemic
growth. The shRNA-targeting the Brd4
gene was among the most depleted
shRNAs identifying this gene as important
for AML cell survival. These findings were
further carefully validated using a series of
in vitro and in vivo experiments. The
investigators surmised an essential role
for the gene encoding the proto-oncopro-
tein, c-Myc, since Brd4 was previously
shown to regulate c-Myc expression.
Moreover, c-Myc has long been recog-
nized as a regulator of leukemia biology
and has been suspected to play a role
in the renewal of leukemic stem cells.
However, attempts to target the protein
therapeutically have been unsuccessful.
Hence, c-Myc emerges yet again as a
critical nodal point in the pathogenesis
of leukemias, but its regulation by Brd4
leads to a novel approach to downregu-
lating c-Myc by targeting a chromatin-
associated protein that regulates its
expression.
Bromodomain proteins are a family of
transcriptional regulators implicated in
regulating epigenetic memory. Brd4 is a
member of the BET family of proteins
that is characterized by the presence of
two tandem bromodomains, the only
known direct recognition modules of
acetylated lysines. Brd4 interacts with
P-TEFb and functions as a global tran-Cancer Cell 20, Sescriptional coactivator (Wu and Chiang,
2007; Zeng and Zhou, 2002). Brd4 is
recruited to acetylated histones and
stimulates transcriptional elongation, but
recent results suggest the protein may
play a role in a variety of chromatin regu-
lating complex (Rahman et al., 2011).
Mixed lineage lymphoma (MLL) fusion
proteins of the type used to generate the
animal model studied by Zuber and
colleagues also regulate elongation, and
it is tempting to speculate that elongation
of c-Myc mRNA is a critical Brd4-depen-
dent event, but further experimentation
is necessary to test this hypothesis.
In a remarkable convergence of initially
distinct lines of research, BET proteins
were recently identified as targets of
the related compounds JQ1 and I-BET
(Filippakopoulos et al., 2010; Nicodeme
et al., 2010). Both are first generation,
cell-permeable small molecules that bind
competitively to the acetyl-lysine recogni-
tion motifs with high specificity for the
bromodomains of BET family members
but not other chromatin-associated pro-
teins. BET bromodomains are structurally
well characterized and display well-
defined modes of acetyl-lysine binding,
making them attractive drug targets
when the proteins, as here, have a demon-
strated biologic role in disease mainte-
nance. Zuber et al. showed that JQ1
treatment of numerous leukemic cell lines
involving MLL and non-MLL transloca-
tions, primary leukemic cells, as well as
mice bearing MLL-AF9/Nras G12D
leukemic cells leads to leukemic cell
death, myeloid differentiation and, in theptember 13, 2011 ª2011 Elsevier Inc. 287
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Previewscase of the mice, extended survival, thus
phenocopying the effects of Brd4 knock-
down and further defining Brd4 as an
Achilles heel in a wide range of leukemias.
JQ1 and I-BET bind all examined BET
family proteins. It is therefore possible
that derivatives of these compounds
could be developed that uniquely bind
only one of the tandem bromodomains
or distinguish between BET family pro-
teins to increase their therapeutic value.
Together with previous work on BET
inhibitors, this study impressively demon-
strates that contrary to widespread views,
proteins that lack intrinsic enzymatic
activity and function instead as adaptor
molecules can represent powerful drug
targets. Chromatin-associated proteins
are especially attractive candidates for
pharmacological intervention since some
histone modifications carry the potential
for epigenetic memory. Hence, thera-
peutic benefits might persist beyond the
duration of the treatment.
An unanswered question raised by
these studies is why JQ1 demonstrates
antitumor activity without apparent
toxicity. As noted, JQ1 interacts with all
examined BET proteins, many of which
are essential for development (Houzel-
stein et al., 2002). Moreover, Brd4 is
widely expressed and associates with a
host of genes (Rahman et al., 2011). The
answer likely relates to differential sensi-
tivities to partial Brd4 inhibition/depletion
between highly proliferative cells and
normal, slow growing, or resting cells.
The c-Myc gene, which is bound by
Brd4, is dynamically regulated in part at
the level of transcriptional elongation.288 Cancer Cell 20, September 13, 2011 ª20Brd4 associates with the transcription
elongation complex, P-TEFb, presumably
mediating rapid transitions in transcrip-
tion elongation (Jang et al., 2005; Yang
et al., 2005). Limiting the levels of Brd4 or
its association with acetylated chromatin
might lower productive c-Myc transcrip-
tion, thus slowing the growth of rapidly
dividing cells. Similar molecular mecha-
nisms might account for the anti-inflam-
matory effects of I-BET. Interestingly,
a separate recent study suggests that
Brd4 may be a target for therapy in a rare
disease, NUT midline carcinoma (NMC)
(Filippakopoulos et al., 2010). Taken
together, these observations lead one to
speculate that an increased dependence
on Brd4 may be a common feature of
malignant cells compared to untrans-
formed cells. Why this is so and whether
Brd4 targeting molecules will have a func-
tion in therapy for other malignancies will
be an important area for future studies.
It is a profound curiosity in science that
‘‘what goes around, comes around,’’ or,
in other words, important observations
have a way of repeating themselves. In
a second study by Zuber and colleagues,
the group used a similar short hairpin
approach to identify target genes for
therapy in AML and identified the c-Myb
oncogene as a therapeutic target for
AML. The two studies raise striking echos
of the 1989 article by Anfossie, Gewirtz
and Calabretta stating that c-Myb anti-
sense RNA induced death of AML cells,
whereas c-Myc antisense oligomers in-
duced differentiation of cells with a less
profound induction of cell death (Anfossi
et al., 1989). Thus, although our tech-11 Elsevier Inc.nology moves forward, it would seem
that biology still points us towards the
critical nodes of transformation initially
identified by the study of viral oncogenes
and chromosomal translocations.REFERENCES
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